Hairy Cell Leukemia (HCL) Recruiting Phase 2 Trials for Rituximab (DB00073)

Also known as: Hairy-cell Leukemia / Hairy cell leukaemia / Hairy Cell Leukemia / Leukemia, Hairy Cell / Leukemic reticuloendotheliosis / Hairy cell leukemia (disorder) / Hairy cell leukemia (morphologic abnormality) / Hairy cell leukemia with failed remission / Leukemic reticuloendotheliosis -RETIRED- / Leukaemic reticuloendotheliosis / Leukemic reticuloendotheliosis NOS (disorder) / Leukemic reticuloendotheliosis of unspecified sites (disorder) / [M]Leukaemic reticuloendotheliosis

IndicationStatusPhase
DBCOND0046776 (Hairy Cell Leukemia (HCL))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01059786Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaTreatment
NCT00923013Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell LeukemiaTreatment
NCT00412594Cladribine and Rituximab in Treating Patients With Hairy Cell LeukemiaTreatment